You are here

  • Home
  • Archive
  • Volume 16, Issue 6
  • In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol
  1. Tom Kovesi
  1. Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
  1. Correspondence to Tom Kovesi
    Department of Pediatrics, University of Ottawa, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; kovesi{at}cheo.on.ca

https://doi.org/10.1136/ebm1411

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:650–7.OpenUrlCrossRefPubMedWeb of Science

    Context

    Many studies have shown that regular use of inhaled corticosteroids improves asthma control in children with asthma. However, intermittent therapy with inhaled corticosteroids is common practice in the community1 as many physicians and families are reluctant to administer inhaled corticosteroids long term. Several previous studies have examined this approach and have generally not found it to be convincingly effective. The investigators wished to evaluate the efficacy of this approach in children potentially ready to be ‘weaned off’ inhaled corticosteroids. Their findings add to the body of literature evaluating the efficacy of intermittent therapy with inhaled corticosteroids in children with mild, persistent asthma.

    Methods

    This was a large, multicentre, randomised, double-blind, placebo-controlled trial that employed a two-by-two factorial design. Between January 2007 and May 2009, the study enrolled children aged 6–18 years with a history mild, persistent asthma for the previous 2 years, who were felt to be eligible for ‘weaning’ …

    View Full Text

    Footnotes

    • Competing interests TK has received honoraria from AstraZeneca Canada, Nycomed Canada and Merck Frosst Canada.